<DOC>
	<DOCNO>NCT00062556</DOCNO>
	<brief_summary>The purpose study evaluate Niacin ER/Lovastatin , two different dos , compare diet control ( group receive tablet contain 50 mg. immediate-release niacin ) safe effective medicine subject leg pain cause narrowing leg artery , condition call intermittent claudication . At least 366 subject leg pain cause narrowing leg artery participate study . Niacin ER/Lovastatin combination two FDA ( United States Food Drug Administration ) approve cholesterol modify medication : Niaspan® ( extended-release niacin ) lovastatin , statin ( medicine find Mevacor® ) . Niacin ER/Lovastatin approve FDA name Advicor® use treatment elevate cholesterol . The use Niacin ER/Lovastatin treatment peripheral arterial disease symptomatic relief intermittent claudication consider investigational . An investigational use one approve FDA .</brief_summary>
	<brief_title>Effect Niacin ER/Lovastatin Peak Walking Time &amp; Claudication Onset Time Patients With Intermittent Claudication</brief_title>
	<detailed_description>This Phase 3 , 28-week , double-blind , diet-intervention , randomize , parallel group , three-arm , multi-center , dose-titration study . The objective study evaluate safety efficacy NL patient IC . The primary efficacy analysis percent change baseline Peak Walking Time ( PWT ) Claudication Onset Time ( COT ) , calculate logarithm quotient time walk treadmill visit divide time walked baseline . Other efficacy measure include Ankle Brachial Index ( ABI ) , QoL measurement , composite cardiovascular event ( MI , stroke , vascular death , low limb amputation ) , coronary peripheral artery revascularization procedure . Safety variable include serum transaminase , routine chemistry parameter , hematology , AEs . Pharmacokinetic analysis conduct well .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>INCLUSION CRITERIA : Men &amp; woman least 40 year age old . Women must pregnant breastfeed &amp; plan become pregnant breastfeed . History IC low extremity present least 6 month change symptoms previous 3 month prior screen . LDLC &lt; 160 mg/dL Triglycerides &lt; 800mg/dL . EXCLUSION CRITERIA : Severe neuropathy Gross obesity ( BMI ≥ 40 ) Presence critical limb ischemia define ischemic rest pain , gangrene , ulceration , pending amputation low extremity due severe PAD . Surgical intervention alleviate symptom claudication within 6 month endovascular intervention within 3 month Documented CAD take cholesterolmodifying agent Systolic blood pressure ≥ 160 mmHg &amp; /or diastolic blood pressure ≥ 95 mmHg Presence clinically significant laboratory test abnormality liver renal function test HgbA1C . History alcohol abuse currently drink alcohol excess .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Intermittent Claudication</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Niacin</keyword>
	<keyword>Lovastatin</keyword>
	<keyword>PAD</keyword>
	<keyword>IC</keyword>
</DOC>